
IRISH JOURNAL OF **PSYCHOLOGICAL** MOLIANO A DECEMBER 1997 **MEDICINE** ISSN 0790-9667



ZimovaneTM zopiclone

23 million sleep nights in Ireland since launch

Zimovane is manufactured for the world in Nenagh, Co. Tipperary.

Prescribing Information: Presentation: White elliptical tablet containing 7.5mg Zopiclone. The tablet also contains lactose and wheat starch. Pharmacology: Zopiclone a cyclopytrolone derivative, has a pharmacological profile resembling a benzodiazepine Indications: Short term management of insomia which is sever, disabiling or subjecting the individual to extreme distress. Desage and Administration: Adults: 7.5mg shortly before retiring. Elderly: An initial dose of 3.75mg is recommended. Dusage should be kept to a minimum. Children: Not established. To some you be the exceeded. Zopiclone is removed by dialysis. Contraindlealions: Evenance with a 3.75mg. Benal insufficiency: a starting dose 3.75mg. Daily dose of 7.5mg is recommended. Dusage should be kept to a minimum. Children: Not established. Sopicione is removed by dialysis. Contraindlealions: Children: Not established. Sopicione is nervoused by dialysis. Contraindlealions: Children: Not established or 3.75mg gradually decreased. There is an absence of any marked tolerance with Zimovane for treatment periods of up to four weeks. Interactions: Alcohol, CNS depressants, compounds that inhibit cyclortorme P450. Adverse Effects: Bitter taste is the most common side effect, drowsiness during the day or incoordination, headache, diaziness, and dry elder/s. Should persession and nervousness, amnesia, automatism, inappropriate behaviour, confusion, nightmare, hangover and Gl disturbance, these reactions are more likely to occur in the eldersy. Should perspective of starteness. Protect from light. Store in a dry place below 25°C. Zimovane is a trademark, GMS Highs?//doi.org/10.1017/S0790966700003281Published/9/femamark. Bangover frequence is a reademark, GMS https://doi.org/10.1017/S0790966700003281Published/9/femamark.Bangover and Bistress and and a strademark. Bangover and Bistress and and and and advector in the secret related 1997. Legal Category: SI.A. Prescription Only Medicine. Editor-in-Chief: Brian Lawlor

Editorial Assistant: Niamh Gleeson

Advertising Manager:

Mary Kate O'Flanagan

Founding Editor: Mark Hartman

Editors: Timothy Dinan (London), David King (Belfast)

Deputy Editor: Brian O'Shea (Dublin)

Associate Editors: Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary)

Statistical Editor: Leslie Daly (Dublin)

Deputy Statistical Editor: Ronan Conroy (Dublin)

Submissions & correspondence to: The Editor,

trish Journal of Psychological Medicine, 99 Upper George's Street, Dun Laoghaire, Co Dublin.

Telephone 01-2803967; Int: +353-1-2803967

Fax

01-2807076; Int: +353-1-2807076

Publisher

MedMedia Ltd. Media House, 99 Upper George's Street, Dun Laoghaire, Co Dublin.

Printing: New Cityview Press

Subscriptions

Rates per volume of four issues (Mar, Jun, Sept, Dec) STG£43 EU, US\$96 USA, STG£53 elsewhere (single issues US\$28 USA, STG£13.25 elsewhere) incl. airmail postage internationally.

Subscription enquiries, orders and cheques made payable to:

Royal Society of Medicine Press Ltd., 1 Wimpole St,

London, W1M 8AE, UK. Tel: 0171-2902927; int: +44-171-2902927. Fax: 0171-2902929; int: +44-171-2902929.

Circulation

3,000 to 54 countries. Journal participates in the World Health Organisation project to improve distribution of scientific materials on mental health. Publication does not imply endorsement. Limited photocopying authorisation granted for a fee to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA, or to appropriate Reproduction Rights Organisation; isolated non-profit, academic photocopying excepted.

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 14 NO 4 DECEMBER 1997 ISSN 0790-9667

EDITORIAL

121 Cogito ergo sum? - refocusing dementia ethics in a hypercognitive society Desmond O'Neill

ORIGINAL PAPERS

- 124 Hopelessness and suicidal feelings among the community dwelling elderly in Dublin
 - Michael Kirby, Irene Bruce, Alicja Radic, Davis Coakley & Brian A Lawlor
- 128 Lack of gender differences in familial schizophrenia Bernadette M Murphy, John G Burke, Joseph C Bray, Dermot Walsh & Kenneth S Kendler

BRIEF REPORTS

- 132 Object relations theory applied to early emotional deprivation, resulting in autistic spectrum disorder Siobhan Rooney & Gerard Byrne
- 136 Using the Achenbach Child Behaviour Checklist in the differential diagnosis of disruptive behaviour disorders Thomas P Kelly & Paul McArdle

REVIEW

139 Platelet studies in panic disorder: a review

Laura Mannion, Desmond Nugent & Brian Leonard

PERSPECTIVE

144 Suicide as altruism: A Darwinian perspective Riadh T Abed

CASE REPORTS

- 147 Reintroduction of antipsychotics in a patient with clozapine induced neuroleptic malignant syndrome Kelwyn Williams & Rob MacPherson
- 149 Folie a famille the need for family perspectives in psychiatry Mark McCartney & Rachel Leheup
- 151 Hypertension and increased serum clozapine associated with clozapine and fluoxetine in combination Darina Sloan & James O'Boyle

131 Guidelines for authors

- 138 Announcement of IJPM Website
- 143a John Dunne Medal
- 153 Letters to the Editor
- 156 Index to key words 1997
- 157 Index to authors 1997

Cover illustration: 'A frost piece', James Arthur O'Connor (c. 1792-1841)

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycIIT); Cumulative Index to Nursing & Allied Health Literature; Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Socialgical Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.



Fast Response Gan start to improve symptoms Within seven days

LUSTRAL 50 mg A first choice antidepressant



Abbreviated Prescribing Information: LUSTRAL™ (sertraline)

Presentation: Tablets containing 50mg or 100mg sertraline. Indications: Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). Dosage: Lustral should be given as a single daily dose.

Usstal should be given as a single, Jossage. The initial dose is 50mg and the usual antidepressant dose is 50mg. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be monitored. Although maintained on the lowest effective dose. Use in children: Not recommended. Use in elderly: Usual adult dose. Contra-indications: Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable pelpepsy and convulsant disorders, pregnancy and lactation. https://boi.noguse.withy.orwithin.twooweeks:ofrendileg.deatmentby/taminadgeaund/artigea/basse stools, ejaculatory delay, tremor,

MAOI's. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquillizers in patients who drive or operate machinery. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs such as tryptophan or fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol is concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects:** Dry mouth, neutron distrabered heaves, chone cisculatory dolay.

increased sweating, dizziness, insomnia, somnolence, headache and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no casual relationship: movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea and rash. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. As with all psychoactive medicines, possible side effects on discontinuation, such as dizziness, sensory disturbance, sleep disturbance, agitation or anxiety, nausea and sweating. Legal Category: 51A. Package Quantities: Somg tablet (PA 822/1/4) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. Product Authorisation Holder: Pfizer (Ireland) Limited, Pharmapark, Chapelizod, Dublin 20, Republic of Ireland. Further information on request: Pfizer (Ireland)

information on request: Pfizer (Ireland) Limited. Date last revised: 1/11/96 66973 June 97

